Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated at StockNews.com

Posted by ABMN Staff on Apr 26th, 2025

Analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the basic materials company’s stock.

Arcadia Biosciences Stock Performance

Shares of RKDA stock opened at $3.45 on Thursday. The company has a market capitalization of $4.72 million, a price-to-earnings ratio of -0.81 and a beta of 0.78. Arcadia Biosciences has a 52-week low of $1.93 and a 52-week high of $10.31. The company has a 50-day simple moving average of $3.28 and a two-hundred day simple moving average of $4.13.

Institutional Trading of Arcadia Biosciences

An institutional investor recently bought a new position in Arcadia Biosciences stock. Geode Capital Management LLC bought a new position in shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned 0.90% of Arcadia Biosciences at the end of the most recent reporting period. 17.73% of the stock is owned by institutional investors and hedge funds.

About Arcadia Biosciences

(Get Free Report)

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.